HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Probucol (Lorelco)

A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

Also Known As:

Lorelco; Almirall Brand of Probucol; Aventis Brand of Probucol; Biphenabid; DH-581; Hoechst Brand of Probucol; Lurselle; Panavir; Superlipid; DH 581; DH581; Phenol, 4,4'-((1-methylethylidene)bis(thio))bis(2,6-bis(1,1-dimethylethyl))-

Networked: 557 relevant articles (82 outcomes, 122 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Phenols: 309
  - Probucol: 557

Experts

1.	Stocker, Roland: 9 articles (03/2012 - 08/2002)
2.	Tardif, Jean-Claude: 8 articles (05/2006 - 01/2002)
3.	Litvin, A A: 7 articles (11/2011 - 01/2006)
4.	Wu, Ben J: 6 articles (03/2012 - 09/2004)
5.	Yamashita, Shizuya: 5 articles (08/2015 - 11/2005)
6.	Liu, Tong: 5 articles (02/2015 - 02/2009)
7.	Farina, Marcelo: 5 articles (04/2013 - 03/2012)
8.	Singal, P K: 5 articles (04/2005 - 04/2000)
9.	Li, Guangping: 4 articles (02/2015 - 02/2009)
10.	Fan, Jianglin: 4 articles (01/2015 - 01/2013)

Related Diseases

1.	Atherosclerosis 09/06/1996 - "The results demonstrate that although probucol provided a significant protection against Cu(2+)-induced oxidative modification of LDL, it lacked effect on the development of femoral atherosclerosis. " 02/01/1992 - "Thus, probucol was effective in preventing atherosclerosis in long-term studies at both early and late stages." 02/01/1992 - "In the second study (study B), administration of probucol was commenced with 8-month-old WHHL rabbits to investigate whether the drug was effective for limiting atherosclerosis in rabbits in which plaques had already developed. " 01/01/2000 - "Protective effects of probucol in two animal models of atherosclerosis." 02/01/2013 - "Probucol, an antioxidant and anti-inflammatory agent counteracting atherosclerosis and restenosis, is partially effective by influencing suicidal cell death or apoptosis. "
2.	Hypercholesterolemia 12/01/1997 - "Our report underlines that probucol can still provide a valuable option for the treatment for hypercholesterolemia, being particularly effective in patients with a combined increase of LDL-C and HDL-C levels." 05/01/2002 - "Probucol is also used for hypercholesterolemia and recently is known that it prevent the restenosis of the coronary artery after PTCA. " 07/01/1999 - "They also suggest that the reduction of hypercholesterolemia after the change in diet or treatment with probucol suppressed glomerular injury by suppressing the glomerular MCP-1 expression. " 01/01/1998 - "Evaluation of effectiveness of hypolipidemic action of probucol in doses 500 and 1000 mg/day and comparison of probucol blood concentrations on the treatment month 3 and 6. Probucol (Akrikhin, Russia) was given to 41 patients with primary hypercholesterolemia in a dose 500 mg/day. " 10/01/1997 - "Probucol is used to treat hypercholesterolemia and also has an anti-atherogenic effect. "
3.	Cardiomyopathies (Cardiomyopathy) 06/01/1994 - "The study suggests potential usefulness of antioxidant (probucol) therapy in ADR cardiomyopathy." 11/01/2003 - "Probucol has been reported to completely prevent DOX-induced cardiomyopathy. " 06/01/2000 - "An increase in oxidative stress, GSHPx inactivation and MnSOD downregulation during ADR cardiomyopathy were prevented by probucol treatment." 06/01/2000 - "Probucol has been reported to completely prevent ADR cardiomyopathy without interfering with its antitumor effects. " 10/01/2009 - "Attention should be drawn to probucol, a lipid-lowering agent with potent antioxidant properties, which provides complete protection against Dox-induced cardiomyopathy in rats without interfering with the antitumor properties of Dox in an experimental setting. "
4.	Proteinuria 02/28/2002 - "A significant reduction in proteinuria was seen during the probucol treatment (median (range): 6.4 (3.8-9.1) g/d vs. 4.7 (1.3-16) g/d; P < 0.05), with partial remission achieved in four patients. " 12/01/1996 - "These structural changes within the GBM could be of functional relevance because treatment with the potent LPO-antagonist probucol reduces proteinuria by < 80%. " 10/01/1994 - "The close temporal correlation of the occurrence of LPO with proteinuria and the ability of probucol to inhibit proteinuria support a causal role for LPO in the the alteration of the glomerular permselectivity which results in proteinuria." 10/01/1994 - "When LPO was inhibited by pretreatment of PHN rats with the antioxidant probucol, proteinuria was reduced by approximately 85%, and glomerular immunostaining for dialdehyde adducts was markedly reduced, even though the formation of immune deposits was not affected. " 03/01/2006 - "In conclusion, our study provides the first evidence that the antioxidant probucol, when added to an Ang II receptor blockade, fully arrests proteinuria and disease progression in GN. "
5.	Xanthomatosis (Xanthoma) 04/01/1992 - "This effect implies that probucol can be effective for treatment of atheromatous lesions, because xanthoma is a lesion which consists of macrophage-derived foam cells. " 05/01/2013 - "Plane xanthoma is primarily treated with excisional or abrasive therapies; however, probucol can be a safe and effective alternative therapy for DNPX." 05/01/2013 - "Successful treatment of diffuse normolipemic plane xanthoma with probucol." 04/01/1992 - "However, the precise mechanism of probucol in causing regression of xanthoma has not been clarified. " 03/01/1990 - "Moreover, there are some clinical reports that probucol causes a regression of cutaneous and tendon xanthomas in homozygous FH patients. "

Related Drugs and Biologics

1.	Cholesterol
2.	Lipid A
3.	Antioxidants
4.	Doxorubicin (Adriamycin)
5.	cilostazol (Pletal)
6.	HDL Cholesterol
7.	Lipoproteins (Lipoprotein)
8.	Lovastatin (Mevacor)
9.	Pravastatin (Pravachol)
10.	Sirolimus (Rapamycin)

Related Therapies and Procedures

1.	Stents
2.	Angioplasty (Angioplasty, Transluminal)
3.	Drug-Eluting Stents
4.	Intraperitoneal Injections
5.	Balloon Angioplasty